1、 86 43 , , , 1 1 , (P0.05) 1.3 , ( ) , 120 mg/d, 1 1 : 35 g, 20 g, 20 g, 20 g, 15 g, 15 g, 15 g, 12 g, 12 g, 12 g 1 , 300 m L, 2 : 50g, , , 1 1 1 1.4 1) : (VAS) , 1 :0 ;2 ;4 ;6 2) (ESR) (UA) C (CRP) 1.5 8 : , , : , , : , , : , 1.6 SPSS17.0 , t , , P0.05 2 2.1 1 (P0.05) ; 1 , (P0.05) 1 ( 2.2 ESR UA C
2、RP 2 ESR UA CRP (P0.05) , (P0.05) 2.3 3 (P0.05) 2 ESR UA CRP 3 (n) 3 , 0.15%0.67%9 , , , , , , 10-11 , , , , , , 12-13 , , , , , , , , , , , , , , , , , , , , , , , , , , ; , , , , , , ; , , , , , , , , ; 14-15 , , , 16-17; , 18, , ; ; ; , ; , , , , , , , , VAS ESR CRP UA , , , , UA , , 1 . J. , 201
3、3, 29 (11) :913-920. 2 , . J. , 2014, 23 (5) :894-896. 3Behrens MD, Wagner WM, Krco CJ, et al.The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunityJ.Blood, 2008, 111 (19) :1472-1479. 4Nuki G.Colchicine:its mechanism of action and efficacy in crystal induced infl
4、ammationJ.Curr Rhenmatol Rep, 2008, 10 (3) :218-227. 5 , . M. : , 2008:531-540. 6Khanna D, Fitzge rald JD, Khanna PP, et al.2012 American College of Rheumatology guidelines for management of gout.Part1:systematic nonpharm acologic and pharm acologic the rapeuticapproaches to hype r-uricemiaJ.Arthrit
5、is Care Res (Hoboken) , 2012, 64 (10) :1431-1446. 7 , , . M. : , 2009:434-439. 8 . : M. : , 1994:31-32. 9 . J. , 2013, 29 (11) :913-920. 10 , . J. , 2015, 6 (3) :1-3. 11 , . J. , 2013, 17 (9) :631. 12 , , , . J. , 2014, 29 (9) :2013-2015. 13 , , . M. : , 2015:81-91. 14 , , , . NGAL KIM-1 J. , 2014, 15 (3) :201-204. 15 , , , . J. , 2014, 33 (5) :69-72. 16 . J. , 2015, 37 (2) :74-75. 17 , . J. , 2015, 6 (3) :1-3. 18 , , . J. , 2014, 35 (9) :1270-1271.
